Idioma:

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Attal, Michel ; Lauwers-Cances, Valerie ; Marit, Gerald ; Caillot, Denis ; Moreau, Philippe ; Facon, Thierry ; Stoppa, Anne Marie ; Hulin, Cyrille ; Benboubker, Lofti ; Garderet, Laurent ; Decaux, Olivier ; Leyvraz, Serge ; Vekemans, Marie-Christiane ; Voillat, Laurent ; Michallet, Mauricette ; Pegourie, Brigitte ; Dumontet, Charles ; Roussel, Murielle ; Leleu, Xavier ; Mathiot, Claire ; Payen, Catherine ; Avet-Loiseau, Hervé ; Harousseau, Jean-Luc

The New England journal of medicine, 2012-05, Vol.366 (19), p.1782-1791 [Periódico revisado por pares]

Waltham, MA: Massachusetts Medical Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Autor: Attal, Michel ; Lauwers-Cances, Valerie ; Marit, Gerald ; Caillot, Denis ; Moreau, Philippe ; Facon, Thierry ; Stoppa, Anne Marie ; Hulin, Cyrille ; Benboubker, Lofti ; Garderet, Laurent ; Decaux, Olivier ; Leyvraz, Serge ; Vekemans, Marie-Christiane ; Voillat, Laurent ; Michallet, Mauricette ; Pegourie, Brigitte ; Dumontet, Charles ; Roussel, Murielle ; Leleu, Xavier ; Mathiot, Claire ; Payen, Catherine ; Avet-Loiseau, Hervé ; Harousseau, Jean-Luc
Assuntos: Adult ; Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Antineoplastic Agents ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Autografts ; Biological and medical sciences ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Cancer ; Care and treatment ; Chemotherapy ; Clinical trials ; Consolidation ; Disease-Free Survival ; Dose-response relationship (Biochemistry) ; Double-Blind Method ; Drug dosages ; Drug therapy ; Drugs ; Female ; Follow-Up Studies ; General aspects ; Humans ; Immunodeficiencies. Immunoglobulinopathies ; Immunoglobulinopathies ; Immunopathology ; Kaplan-Meier Estimate ; Life Sciences ; Maintenance Chemotherapy ; Male ; Medical sciences ; Middle Aged ; Multiple Myeloma ; Multiple Myeloma - drug therapy ; Multiple Myeloma - mortality ; Neoplasms, Second Primary ; Neoplasms, Second Primary - epidemiology ; Patients ; Peripheral neuropathy ; Product/Service Evaluations ; Stem Cell Transplantation ; Stem cells ; Thalidomide ; Thalidomide - adverse effects ; Thalidomide - analogs & derivatives ; Thalidomide - therapeutic use ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Transplantation ; Transplants & implants ; Young Adult
É parte de: The New England journal of medicine, 2012-05, Vol.366 (19), p.1782-1791
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-News-3
content type line 23
Descrição: Lenalidomide maintenance after stem-cell transplantation significantly prolonged progression-free and event-free survival in patients with multiple myeloma. At 4 years, overall survival was similar in the lenalidomide-treated and placebo-treated groups. During the past decade, high-dose chemotherapy with autologous stem-cell transplantation has become the standard treatment for newly diagnosed myeloma in patients younger than 65 years of age. However, the median duration of response after this procedure does not exceed 3 years, and few patients remain free of the disease for more than 10 years. 1 – 4 Relapses are due to the failure of high-dose chemotherapy to eradicate all myeloma cells. Maintenance treatments have been proposed to control the proliferation of residual malignant cells after transplantation. For many years, interferon with or without glucocorticoids was used, 1 , 2 , 5 but this approach was . . .
Editor: Waltham, MA: Massachusetts Medical Society
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Waltham, MA: Massachusetts Medical Society

Buscando em bases de dados remotas. Favor aguardar.